Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TVTAI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN109310885B ADC-8
|
|||||
| Synonyms |
CN109310885B_ADC-8
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Burkitt lymphoma [ICD11:2A85]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
14-19
|
|||||
| Antibody Name |
Rituximab
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD20 (MS4A1)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
CN109310885B ADC-8 linker
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.13 nM | Positive CD20 expression (CD20+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | OVCAR-3 cells | CVCL_0465 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.29 nM | Positive CD20 expression (CD20+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Lung adenocarcinoma | HCC4006 cells | CVCL_1269 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 37.30 nM | Positive CD20 expression (CD20+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian endometrioid adenocarcinoma | IGROV-1 cells | CVCL_1304 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 39.68 nM | Positive CD20 expression (CD20+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian clear cell adenocarcinoma | TOV-21G cells | CVCL_3613 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.